We are live on ! Find out more

Diagnostics & Research
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
TMO icon
1
Thermo Fisher Scientific
TMO
$260B
$260B $703.51 1.51%
DHR icon
2
Danaher
DHR
$165B
$165B $234.52 1.09%
NTRA icon
3
Natera
NTRA
$61.6B
$61.6B $427.25 4%
A icon
4
Agilent Technologies
A
$51B
$51B $180.92 1.93%
WAT icon
5
Waters Corp
WAT
$46.9B
$46.9B $477.17 1.84%
IQV icon
6
IQVIA
IQV
$45.6B
$45.6B $276.95 1.99%
IDXX icon
7
Idexx Laboratories
IDXX
$44.6B
$44.6B $565.86 0.82%
ILMN icon
8
Illumina
ILMN
$43.6B
$43.6B $288.86 3.36%
MTD icon
9
Mettler-Toledo International
MTD
$34B
$34B $1,699.36 0.83%
LH icon
10
Labcorp
LH
$29.6B
$29.6B $365.29 10.3%
DGX icon
11
Quest Diagnostics
DGX
$27.1B
$27.1B $245.78 1.33%
GH icon
12
Guardant Health
GH
$24.8B
$24.8B $184.99 3.89%
MEDP icon
13
Medpace
MEDP
$19.2B
$19.2B $684.85 1.64%
RVTY icon
14
Revvity
RVTY
$18.5B
$18.5B $165.93 2.51%
CRL icon
15
Charles River Laboratories
CRL
$17.7B
$17.7B $371.75 3.6%
ICLR icon
16
Icon
ICLR
$15.8B
$15.8B $205.16 12.1%
QGEN icon
17
Qiagen
QGEN
$10.4B
$10.4B $50.23 0.12%
GRAL icon
18
GRAIL Inc
GRAL
$6.99B
$6.99B $156.48 3.9%
RDNT icon
19
RadNet
RDNT
$5.86B
$5.86B $74.51 1.32%
BLLN icon
20
BillionToOne Inc
BLLN
$5.42B
$5.42B $114.83 0.67%
SHC icon
21
Sotera Health
SHC
$5.28B
$5.28B $18.50 0.05%
ADPT icon
22
Adaptive Biotechnologies
ADPT
$4.52B
$4.52B $28.35 2.49%
VCYT icon
23
Veracyte
VCYT
$4.06B
$4.06B $50.45 0.34%
CDNA icon
24
CareDx
CDNA
$3.77B
$3.77B $72.79 3.2%
NEO icon
25
NeoGenomics
NEO
$2.27B
$2.27B $17.70 2.49%
1
2

Diagnostics & Research Stocks at a Glance

Diagnostics and research companies run laboratory testing, imaging, and analytical services, and supply the instruments behind them. Testing volumes are recurring and largely non-discretionary, while research-tools demand follows pharma and academic R&D budgets.

There are 46 Diagnostics & Research industry stocks tracked by Wall St. Rank, worth a combined $963B.

The largest by market cap are Thermo Fisher Scientific (TMO) at $260B, Danaher (DHR) at $165B and Natera (NTRA) at $61.6B.

Among institutional investors, Guardant Health (GH) drew the most net new fund positions in Q2 2026: 161 funds opened new positions, taking total fund holders up 116 (24%) quarter-over-quarter.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.